PCSA Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PIRKIMAS 142271 min ago

@ $2.43

Išleistas: 12 vas. 2024 @ 22:26

Grąža: -23.67%

Ankstesnis signalas: vas. 6 - 21:26

Ankstesnis signalas: Pardavimas

Grąža: 0.00 %

Live Chart Being Loaded With Signals

Commentary (21 geg. 2024 @ 18:25):

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States...

Stats
Šios dienos apimtis	19 831.00
Vidutinė apimtis	1.48M
Rinkos kapitalizacija	5.30M
EPS	$0 ( 2024-05-20 )
Kita pelno data	( $-0.980 ) 2024-08-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.220
ATR14	$0.00700 (0.38%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-01	Young David	Buy	1 675	Common Stock
2024-01-01	Young David	Sell	518	Common Stock
2024-01-01	Young David	Sell	1 675	Restricted Stock Units
2024-01-01	Stanker James H	Sell	1 675	Restricted Stock Units
2024-01-01	Stanker James H	Buy	1 675	Common Stock

INSIDER POWER
80.51
Last 99 transactions
Buy: 3 005 145 \| Sell: 402 801

Tūris Koreliacija

Ilgas: -0.16 (neutral)

Trumpas: 0.07 (neutral)

Signal:(33.912) Neutral

Processa Pharmaceuticals, Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
VTNR	0.928
UXIN	0.926
VRM	0.924
PLL	0.92
AXDX	0.912
RNAZ	0.91
CNSP	0.904
MHUA	0.897
IRBT	0.896
SNAX	0.893

10 Labiausiai neigiamai susiję koreliacijos
FFNW	-0.912
HQY	-0.886
ADTH	-0.881
SFBC	-0.875
FGFPP	-0.867
ISRG	-0.859
AGNCP	-0.854
FSEA	-0.849
PRAX	-0.847
SRPT	-0.845

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Processa Pharmaceuticals, Koreliacija - Valiuta/Žaliavos

-0.79
( moderate negative )

-0.74
( moderate negative )

0.00
( neutral )

-0.78
( moderate negative )

-0.68
( moderate negative )

0.78
( moderate )

Processa Pharmaceuticals, Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-222.00 (0.00 %)
EPS:	$-0.850

FY	2023
Pajamos:	$0
Bruto pelnas:	$-222.00 (0.00 %)
EPS:	$-0.850

FY	2022
Pajamos:	$0
Bruto pelnas:	$-27.53M (0.00 %)
EPS:	$-68.10

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-0.750

Financial Reports:

No articles found.

Processa Pharmaceuticals, Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Processa Pharmaceuticals,

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytosine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. The company was incorporated in 2011 and is based in Hanover, Maryland.